Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome. - Lundin,J.; Hagberg,H.; Repp,R.; Cavallin-Stahl,E.; Freden,S.; Juliusson,G.; Rosenblad,E.; Tjonnfjord,G.; Wiklund,T.; Osterborg,A. (Blood, 2003)